News ADA: AZ reveals oral GLP-1 data in obesity, diabetes AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.
News ADA: Lilly's weight-loss reveal, and wannabes display wares Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.
News ADA: Safety data offset efficacy for survodutide New data with Zealand/Boehringer's survodutide reinforce its metabolic benefits, but a high discontinuation rate has raised concerns.
News ADA: Vertex closer to weaning type 1 diabetics off insulin A cell therapy developed by Vertex Pharma has allowed 10 of 12 patients with type 1 diabetes to control their blood sugar without insulin.
News ADA: Lilly makes its case for oral GLP-1 orforglipron Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.
News ADA: Novo continues effort to rehabilitate CagriSema Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials are interpreted.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.